Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

IMP1734

Small molecule · Inhibitor of PARP1

Phase 2 Most advanced trial
1 Registered trials

What is IMP1734?

IMP1734 is an orally bioavailable small-molecule inhibitor of PARP1. It blocks PARP1 activity to prevent DNA repair via the base excision repair pathway, leading to accumulation of DNA strand breaks and apoptosis. It is studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
PARP1
Mechanism
Inhibitor of PARP1
Pathways
base excision repair, DNA damage response, apoptosis
Therapy area
Oncology
In trials of
IBO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06253130 Phase 1/2 Advanced Solid Tumor Recruiting IBO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

Other drugs acting on PARP1

Niraparib FDA approved Olaparib FDA approved 2X-121 Phase 2 EIK1004 Investigational Senaparib Investigational Veliparib Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.